Actavis launches generic of Intuniv
Actavis announced that it has launched a generic version of Intuniv (guanfacine hydrochloride), as part of a settlement agreement with Shire, and has begun shipping product. As the first filer, Actavis said it is entitled to 180 days of marketing exclusivity.
The ADHD drug is approved to treat patients ages 6 to 17. For the 12-month period ending June 30, 2014, Intuniv generated US sales of approximately $668 million, according to IMS Health data.